In summary, breast cancers with ER/PR expression 1–10% represent a small but appreciable subset of early-stage HER2-negative disease and mimic the clinical behavior, chemosensitivity, and survival outcomes of TNBC. This evidence concerns the gene ERBB2 and breast cancer.